TickerTalks
Browse all tickers →
TickerTalks›$CON
COCON

Concentra Group Holdings Parent, Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 113% YoY at strong marginsStreet coverage with positive forward estimatesQuiet on X (14 mentions/wk)
$CON·$4.5B·Medical - Care Facilities·Healthcare
$35.36+1.0%YTD+78.8%1Y+70.1%
Price updated 1h ago·X counts updated 23h ago
COCON
$CONConcentra Group Holdings Parent, Inc.
$35.36+1.00%14 posts
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $CON on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

14X posts · last 7 days
Sep 10Sep 27

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CON — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-27

The move is getting stronger, with heavier trading behind it.

Concentra is up 79% YTD on the occupational-health-cycle recovery — a real specialty-medical compounder trading at 18x earnings.

Concentra Group Holdings is a US-listed occupational-medicine and worksite-health provider serving employers. The equity has been the year's cleanest occupational-health-cycle trade at +79% YTD.

  • Growth is real: revenue grew 113% YoY last quarter to $1.18B (comparison distorted by M&A) and Q2 hit $606M with EPS beating by 23% — a scaled occupational-health franchise running growth-cycle economics with 29% gross margin, 78% operating margin (helped by consolidation accounting), and 62% ROIC.
  • The valuation is reasonable: 18x earnings and 1.5x sales at an 8.3% FCF yield — priced like a maturing specialty-medical franchise, so any acceleration in worksite-health expansion goes into the multiple.
  • The tape reflects the setup: shares at the 91st percentile of range, +33% vs the 200-day, and +3.7% vs the 50-day on volume 38% below trend — real institutional accumulation into range highs.

The Nov 5 print is the arbiter: any raise on 2027 worksite-clinic revenue plus commentary on occupational-medicine cycle restarts the accelerating tape; a soft comparable-clinic number or a hint of consolidation-related integration friction is where a name up 79% YTD gives back. This is a real specialty-medical compounder at a reasonable multiple.

What to watch: Nov 5 earnings — 2027 worksite-clinic revenue guide, occupational-medicine cycle commentary, comparable-clinic trajectory, gross-margin trajectory, and any capital-return updates. A revenue raise plus occupational-medicine strength extends the tape; a consolidation-integration friction is the pause trigger.

On the calendar: 2026-11-05 — Q3 earnings

beta missing

Read the AI verdict on $CON

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

US occupational health clinic operator providing workers' compensation injury treatment, urgent care, and employer health services.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Care Facilities sits in its cycle right now — and what that implies for $CON.

Medical - Care Facilities · Healthcare

Hospital system revenue recovery continues as elective procedure volumes normalize and commercial insurance mix improves; Medicaid rate cuts from state budget pressures and CMS site-neutral payment proposals are the margin headwinds. AI revenue cycle automation is reducing denials and accelerating reimbursement timelines, improving cash conversion for systems that adopt it.

What this means for $CON

Neutral — US occupational health clinic operator providing workers' compensation injury treatment, urgent care, and employer health services.

Top industry ETF

$IHFiShares U.S. Healthcare Providers ETF
+16.3%YTD
+15.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
17.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
62.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
77.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
8.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
59.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
28.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
4.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$0.52$0.42+23.3%
Q1 2026May 7, 2026$0.40$0.35+14.3%
Q4 2025Jan 28, 2026$0.28$0.23+23.5%
Q3 2025Nov 6, 2025$0.39$0.37+5.4%
Next earningsThu, Nov 5·consensus EPS $0.45

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$1.2B+113.4%30.8%17.9%$0.91$129.5M
Q1 FY26$569.6M+13.7%26.5%17.0%$0.39$9.9M
Q4 FY25$539.1M+15.9%26.1%338%$0.27$180.9M
Q3 FY25$572.8M+17.0%29.2%16.5%$0.38$39.4M

Forward consensus

3-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.3B$2.3B – $2.4B$1.65$1.62 – $1.687
FY27$2.5B$2.5B – $2.5B$1.84$1.80 – $1.887
FY28$2.6B$2.6B – $2.6B$2.00$1.99 – $2.016

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.91%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+3.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+33.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 114.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.635-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 3Robert A OrtenzioDirector130.0K sh$4.1MSellJul 1Robert A OrtenzioDirector130.0K sh$4.0MSellJun 1Robert A OrtenzioDirector130.0K sh$3.3MSellMay 8Robert A OrtenzioDirector130.0K sh$3.3M
+ 2 other (2 returns) in window

See when $CON insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeSep 88-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

Concentra Group (CON) announced that Matthew DiCanio becomes CEO November 1, 2026, Keith Newton becomes Executive Chairman, and Tanner Newton (age 34) becomes EVP and CFO — all effective November 1. The coordinated leadership transition represents a generational shift in the occupational health services company's executive team.

SC 13D/AActivist amendmentSep 1SC 13D/A
AI summary

Robert A. Ortenzio filed Amendment No. 4 to his Schedule 13D on Concentra Group Holdings Parent, Inc. on September 1, 2026 solely to correct an administrative error in Amendment No. 3 (filed August 24, 2026). The corrected figures show Ortenzio beneficially owns 6,648,222 shares (~5.3% of ~127.5 million shares outstanding as of July 31, 2026), with sole voting power over 4,663,794 and sole dispositive power over 4,763,794 shares. The correction reflects no new transaction or change in ownership intent. Purely a technical filing correction with no strategic implications.

8-KMaterial agreementAug 278-K — Item 1.01: Material agreement
AI summary

Concentra Group Holdings Parent, Inc. entered into a stock repurchase agreement on August 21, 2026 with its Chairman Robert A. Ortenzio and related entities to repurchase 1,000,000 shares of common stock at $34.65 per share (a 1% discount to that day's closing price) for total consideration of $34.65 million, funded from cash on hand and closed August 24, 2026. The transaction was approved by the independent Audit and Compliance Committee; Ortenzio cited portfolio diversification as the reason. A Board-chairman-directed block repurchase at a modest discount returned $34.65M to the chairman while reducing shares outstanding by ~0.8%; related-party approval and committee oversight are standard for such insider block trades.

SC 13D/AActivist amendmentAug 24SC 13D/A
AI summary

Timothy F. Ryan (Concentra Group Holdings, 5080 Spectrum Drive, Addison TX), via counsel Stephen Leitzell at Dechert LLP (Philadelphia), filed Amendment No. 3 to a Schedule 13D on Concentra Group Holdings Parent, Inc. (CON) Common Stock ($0.01 par value) as of August 21, 2026. Ryan appears to be an executive or insider at Concentra who holds a 5%+ stake requiring Schedule 13D reporting. This is the third amendment to his position disclosure for the occupational health services company. The specific update details are not visible in the excerpt.

8-KOfficer or director changeAug 68-K — Item 2.02: Earnings release · Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Concentra Group Holdings Parent, Inc. filed a multi-item 8-K covering Q2 2026 earnings results (quarter ended June 30, 2026), a director or officer change (Item 5.02), a Reg FD disclosure (Item 7.01), and an Other Events item (8.01). The press release was issued August 6, 2026; no headline financials appear in the excerpt. Concentra is a national occupational health company serving employers through workplace health and injury care clinics. This compound filing signals a busy reporting period — the officer change and other events items may be independently material.

8-KOfficer or director changeJul 108-K — Item 5.02: Officer or director change
AI summary

Concentra Group Holdings Parent Inc disclosed a consulting agreement between its subsidiary Concentra Health Services Inc and Dr. John R. Anderson, who is retiring as EVP and Chief Medical Officer effective December 31, 2026. The consulting agreement becomes effective January 1, 2027 and runs through December 31, 2027, under which Anderson will serve as an independent contractor providing part-time consulting services. No financial terms of the consulting arrangement are disclosed in the filing text. This is a routine officer transition arrangement — retaining the departing CMO in an advisory capacity for clinical continuity, with minimal financial impact.

8-KPress release / Reg FDMay 78-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD · Item 8.01: Other event
8-KShareholder voteApr 308-K — Item 5.07: Shareholder vote
+ 5 other (2 10-Qs · 2 13Gs · 1 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

CON EDISON TO WEBCAST INVESTOR PRESENTATION ON OCTOBER 6, 2026prnewswire.com·12d agoConcentra Group Holdings Parent: Potential Beneficiary Of Increased Injuries From Data Center Capexseekingalpha.com·13d agoConcentra Group Holdings Parent, Inc. (CON) Hits Fresh High: Is There Still Room to Run?zacks.com·14d agoConcentra Expands Florida Footprint with New Daytona Beach Medical Centerbusinesswire.com·15d agoCON vs. MEDP: Which Stock Is the Better Value Option?zacks.com·17d ago

More in Medical - Care Facilities

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$HIMS$THC$ASTH$STLN$NUTX$AVAH$NHC$PNTG
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport